Comparative Pharmacology
Head-to-head clinical analysis: SUGAMMADEX versus SUGAMMADEX SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUGAMMADEX versus SUGAMMADEX SODIUM.
SUGAMMADEX vs SUGAMMADEX SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective relaxant binding agent that forms a complex with neuromuscular blocking agents (rocuronium, vecuronium) in plasma, reducing their concentration at the nicotinic receptor.
Selective binding to aminosteroidal neuromuscular blocking agents (e.g., rocuronium, vecuronium), encapsulating them and reducing their concentration at the nicotinic acetylcholine receptor, thereby reversing neuromuscular blockade.
4 mg/kg IV as a single bolus for routine reversal of moderate neuromuscular blockade (train-of-four [TOF] count of 2); 2 mg/kg IV as a single bolus for deep blockade (post-tetanic count [PTC] of 1-2); 16 mg/kg IV as a single bolus for immediate reversal of rocuronium-induced blockade (1.2 mg/kg rocuronium) given 3 minutes after administration.
4 mg/kg IV as a single bolus for routine reversal of moderate neuromuscular blockade (train-of-four count 2); 2 mg/kg IV for deep blockade (train-of-four count 0-1); 16 mg/kg IV for immediate reversal after a single dose of rocuronium 1.2 mg/kg.
None Documented
None Documented
Clinical Note
moderateSugammadex + Dienogest
"The serum concentration of Dienogest can be decreased when it is combined with Sugammadex."
Clinical Note
moderateSugammadex + Medroxyprogesterone acetate
"The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Sugammadex."
Clinical Note
moderateSugammadex + Etonogestrel
"The serum concentration of Etonogestrel can be decreased when it is combined with Sugammadex."
Clinical Note
moderateSugammadex + Norgestrel
Terminal elimination half-life approximately 2 hours (range 1.5-2.5 hours); clinically, recovery from neuromuscular blockade occurs within minutes after administration due to rapid redistribution and encapsulation of rocuronium/vecuronium
Terminal elimination half-life is approximately 2 hours (range 1.5–3 hours); clinically, this supports rapid recovery from neuromuscular blockade.
Primarily renal excretion of unchanged drug; approximately 70% of the dose recovered in urine over 24 hours, with minimal biliary/fecal elimination (<5%)
Primarily renal excretion (approximately 95% of dose excreted unchanged in urine over 24 hours); minimal biliary/fecal elimination (<5%).
Category C
Category C
Neuromuscular Blockade Reversal Agent
Neuromuscular Blockade Reversal Agent
"The serum concentration of Norgestrel can be decreased when it is combined with Sugammadex."